Sanofi-Aventis (SASY.PA) confirmed on Friday that two patients suffered liver failure after taking its heart drug Multaq, but said no causal link had been established with the medicine. The French drugmaker, whose shares were down 1.6 percent by 1300 GMT, said it had written to U.S. healthcare professionals informing them of two cases of hepatic failure resulting in liver transplantation in two patients taking Multaq. The CardioBrief website earlier reported that the patients were women in their 70s who developed liver failure after taking Multaq, or dronedarone, for four to six months (cardiobrief.org/).
Source
